|
|
||||||||
Division of Pulmonary and Critical Care, Dept of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
CORRESPONDENCE: S. D. Shapiro, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston 02115, MA, USA. Fax: 1 6177327421. E-mail: sdshapiro{at}partners.org
Keywords:
1-Antitrypsin, chronic obstructive pulmonary disease, collagenase, gene-targeted mice, tumour necrosis factor-ß, transgenic mice
Received: July 3, 2006
Accepted October 25, 2006
| ABSTRACT |
|---|
|
|
|---|
There are many examples in the literature of transgenic mice that have contributed to the understanding of COPD. Several studies demonstrate the complexity of inflammatory networks and how unexpected findings in animal models have led to the search for new potential mediators in human disease.
Gene-targeting studies into
1-antitrypsin (
1-AT) and emphysema in mice have demonstrated that the genetic locus for
1-AT in mice is very complex and that the loss of one gene is lethal in embryo lung development. This underlines the differences between mice and humans that limit the ability to translate between systems in some instances. Gene targeting has also highlighted complex roles for transforming growth factor-ß in COPD and has been used to determine important molecules and pathways in COPD.
Both transgenic and gene-targeted models suffer limitations and their applicability to human chronic obstructive pulmonary disease may be dependant on several factors, some of which are still being learnt. The more that is known about similarities and differences, the better the knowledge will be that is gained to develop for chronic obstructive pulmonary disease.
Animal models have played an important role in the understanding of the pathogenesis of chronic obstructive pulmonary disease (COPD). Animal models figured prominently in the origin of the elastaseantielastase hypothesis in the 1960s, when Gross et al. 1 found that instillation of elastases led to emphysema in rodents. With the advent of genetic engineering, the capacity is now available to specifically overexpress and delete individual gene products in mice, allowing for highly controlled experiments in mammals. These techniques provide opportunities to dissect disease pathways in vivo. However, the applicability of findings to human COPD depends upon several factors, including the disease model, and similarities in mouse structure and function between species. The present authors hypothesis is that general mechanisms are likely to be well conserved, but important details may differ considerably; hence, care in translation from mouse to humans is required.
| TRANSGENIC MICE |
|---|
|
|
|---|
|
One of the earliest applications of transgenic technology to COPD was the overexpression of collagenase-1 (matrix metalloproteinase (MMP)-1) resulting in airspace enlargement 3. This challenged the elastaseantielastase hypothesis, thereby placing collagen squarely in the picture. A limitation of the study 3 is that while expression was lung specific in some lines (despite being driven by the haptoglobin promoter), it was not inducible. However, the authors did not detect expression of collagenase in some lines during early development. The role of collagen in COPD is complex. Clearly, destruction of an alveolar unit requires loss of all cells and extracellular matrix including collagen; however, total collagen content in COPD is actually increased, with submucosal airway fibrosis likely to contribute to airflow obstruction. Polymorphisms in the collagenase promoter that cause higher levels of collagenase expression actually correlated with protection against decline in forced expiratory volume in one second in the large lung health study population 4. However, mice do not possess MMP-1 but do express the two other MMP collagenases (MMP-8, neutrophil collagenase or collagenase-2, and MMP-13 collagenase-3), which compensate for lack of collagenase-1 in rodents.
Overexpression of interleukin (IL)-13 5 and interferon (IFN)-
6 represent two important examples of inducible, conditional transgenes leading to emphysema in adult mice. Overexpression of the T-helper cell (Th)2 cytokine IL-13 resulted in inflammation and lung destruction that was metallo- (MMP-9 and MMP-12) and cysteine proteinase-dependent. These mice also exhibit airway remodelling with goblet cell hypertrophy and subepithelial collagen deposition. MMP-9-mediated transforming growth factor (TGF)-ß activation was responsible for collagen remodelling in this model 7. Whether IL-13 is overexpressed in human COPD is currently under investigation. This mouse also supports the "Dutch hypothesis", which states that asthma and COPD have common underlying mechanisms. Overexpression of the Th1 cytokine IFN-
also resulted in inflammation and proteinase-dependent emphysema. Compared with the IL-13 transgenic mouse, the inflammatory component with IFN-
was more subtle, apoptosis was prominent, and there was no associated airway pathology. These are just two examples that demonstrate the complexity of inflammatory networks and how unexpected findings in animal models have led to the search for new potential mediators in human disease.
Gene-targeted mice
Prior to the advent of gene targeting, several natural mutant mice were known to develop airspace enlargement, including tight skin (Tsk+/-) 8, pallid 9, blotchy 10, 11 and beige mice 12. The genetic defects for these mice have subsequently been uncovered. Tsk mice have a mutation in fibrillin-1, a matrix protein that is an important component of elastic fibres 13. While the consequences of this mutation on lung development and repair are clear, the relationship between the genetic defects in the other natural mutant mice to lung structure is not yet apparent. Emphysema in some of these strains, such as the pallid mouse 14, has been attributed to reduced
1-antitrypsin (
1-AT) levels; however, if similar to humans, the levels of
1-AT are not low enough to cause emphysema. In fact, the genetic locus for
1-AT in the mouse is very complex, with four to five genes (depending upon the strain) that encode proteins >95% homologous to each other 15, two of which inhibit neutrophil elastase 16. Knocking out one of these genes (
1-AT no. 2), which only inhibits one-third of neutrophil elastase activity, is lethal in the embryo prior to lung development (unpublished data). This highlights differences between mice and humans that limit the ability to translate between systems in some instances.
Loss of function by gene targeting during foetal development may also result in abnormal lung development and consequent airspace enlargement. While this is not pulmonary emphysema per se, the lack of a critical constituent does suggest that the protein is necessary for development. There are now many examples of gene-targeted mice that undergo abnormal alveogenesis, including mice with loss of transcription and growth factors. For example, members of the large family of fibroblast growth factors (FGF) are essential for several stages of mammalian lung development. Lungs of gene-targeted mice lacking receptors for both FGF receptor-3 and -4 (but not single knockouts) have markedly impaired alveogenesis with increased synthesis of collagen 17. Platelet-derived growth factor-A null mice lack myofibroblasts, which are a key source of tropoelastin and are required for alveolar septation 18, 19. Mice deficient in extacellular matrix proteins, particularly those involved in elastic fibre formation, develop airspace enlargement 20. Elastin -/- mice die within 48 h of birth, which precedes alveolarisation, but abnormal lung development can be appreciated then and in heterozygous mutant mice 21. Loss of microfibrillar proteins, such as latent TGF-ß binding protein-3 22, -4 23, fibulin-5 24, and fibrillin-1 20, all also have abnormal lung development.
The Tsk +/- mice previously described have markedly abnormal lung development 25. The abnormality of lung structure secondary to loss of fibrillin-1 allows sequestration of TGF-ß within the matrix and this appears to lead to abnormal alveolar septation 25. Interestingly, administration of TGF-ß-neutralising antibody to these mice postnatally produced an increase in alveolar septation.
Use of gene-targeted mice has also demonstrated complex roles for TGF-ß in COPD. TGF-ß -/- mice die of overwhelming inflammation within 1 month of birth, limiting their utility to study COPD. However, mice deficient in the ß6-integrin, lacking avb6, fail to activate latent TGF-ß within the lung. These mice also develop macrophage-rich inflammation with excess MMP-12 production. Avb6 -/- mice undergo normal alveolar development but, over time, they develop spontaneous emphysema 26. It is known that TGF-ß inhibits MMP-12 production. Back-crossing avb6 -/- to MMP-12 -/- mice abrogates emphysema, as does crossing these mice to transgenic mice overexpressing TGF-ß. Although total absence of TGF-ß releases the brakes on inflammation, too much TGF-ß leads to airway fibrosis, another important component of COPD. The ß6-deficient mouse represents an example of a gene-targeted mouse with normal development but spontaneous emphysema with ageing. This represents another use of gene-targeted mice to determine important molecules and pathways in COPD.
Limitations of transgenic and gene-targeted mice
Transgenic technology depends upon random introduction of the gene of interest into the recipient genome. This may interfere with the function of other genes, and thus obtaining identical phenotypes in multiple founders is important to assure that the phenotype is related to the transgene itself and is not an integration effect. Gene targeting is based upon homologous recombination of the mutation within the genetic locus of the gene of interest and does not suffer from this limitation.
As discussed, loss of a gene with a resultant phenotype implies that it plays an important functional role, particularly if applied to a disease model. Introduction of a transgene resulting in a phenotype suggests that it could mediate this phenotype if overexpressed in the disease but is not necessarily relevant. For example, with respect to lung development, expression of a transgene during alveogenesis may lead to developmental emphysema impairing interpretation of its effect on pulmonary emphysema (destruction of mature alveoli). Gene targeting might also lead to abnormal development, the difference here being that developmental airspace enlargement with gene targeting suggests a true developmental role for this gene, whereas artificial overexpression of a transgene does not.
Mice in any given inbred background are genetically identical; however, when mice are not on a pure background, phenotypic differences may be related to background strain differences rather than the genetic manipulation itself. Littermates in the mixed background help but, depending upon the phenotype, might not suffice.
The greatest concern, of course, is the utility of mouse studies in predicting human pathophysiology and pathogenesis. The mouse lung has the same general structure and physiological mechanisms as the human lung; however, there are notable exceptions that make translation to humans difficult. For example, the mouse airway has few submucosal glands and only six to eight branches until the terminal bronchiole is reached, which goes directly to the alveolar duct. Humans have >20 branches before becoming the respiratory bronchiole, a structure not present in mice, which is the site of initial inflammation and genesis of centriacinar emphysema. In addition, mice do not always express proteins identical to those in humans, as seen in the previous example of MMP-1. However, while structure and participation in function may differ, the present author maintains that the general pathological pathways in response to stress (for example, cigarette smoke) are conserved; hence, a unique understanding of human pathobiology can be gained via manipulation of the mouse genome. The precision of the translation will depend on a number of factors, some of which are still being learnt about now. The more that is known about both similarities and differences, the better the knowledge will be that is gained from genetic engineering in mice to develop therapy for chronic obstructive pulmonary disease.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
1-antitrypsin deficiency. Lab Investig 1993;68:233241.[ISI]
1-protease inhibitor genes show unusual evolutionary divergence. Proc Natl Acad Sci USA 1991;88:94179421.This article has been cited by other articles:
![]() |
A. Punturieri, T. L. Croxton, G. G. Weinmann, and J. P. Kiley Chronic Obstructive Pulmonary Disease: A View from the NHLBI Am. J. Respir. Crit. Care Med., September 1, 2008; 178(5): 441 - 443. [Full Text] [PDF] |
||||
![]() |
R. H. Brown, C. G. Irvin, G. B. Allen III, S. D. Shapiro, W. J. Martin, M. R. J. Kolb, D. M. Hyde, G. F. Nieman, D. D. Cody, M. Ishii, et al. An Official ATS Conference Proceedings: Advances in Small-Animal Imaging Application to Lung Pathophysiology Proceedings of the ATS, July 15, 2008; 5(5): 591 - 600. [Full Text] [PDF] |
||||
![]() |
S. J. Moghaddam, C. G. Clement, M. M. De la Garza, X. Zou, E. L. Travis, H. W. J. Young, C. M. Evans, M. J. Tuvim, and B. F. Dickey Haemophilus influenzae Lysate Induces Aspects of the Chronic Obstructive Pulmonary Disease Phenotype Am. J. Respir. Cell Mol. Biol., June 1, 2008; 38(6): 629 - 638. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Wert Does adiponectin play a role in pulmonary emphysema? Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1032 - L1034. [Full Text] [PDF] |
||||
![]() |
C. P. Hersh, D. L. DeMeo, and E. K. Silverman National Emphysema Treatment Trial State of the Art: Genetics of Emphysema Proceedings of the ATS, May 1, 2008; 5(4): 486 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Churg, M. Cosio, and J. L. Wright Mechanisms of cigarette smoke-induced COPD: insights from animal models Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L612 - L631. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Emami, R. V. Cadman, J. M. Woodburn, M. C. Fischer, S. J. Kadlecek, J. Zhu, S. Pickup, R. A. Guyer, M. Law, V. Vahdat, et al. Early changes of lung function and structure in an elastase model of emphysema--a hyperpolarized 3He MRI study J Appl Physiol, March 1, 2008; 104(3): 773 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Mizgerd and S. J. Skerrett Animal models of human pneumonia Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L387 - L398. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hoshino, S. Kato, N. Oka, H. Imaoka, T. Kinoshita, S. Takei, Y. Kitasato, T. Kawayama, T. Imaizumi, K. Yamada, et al. Pulmonary Inflammation and Emphysema: Role of the Cytokines IL-18 and IL-13 Am. J. Respir. Crit. Care Med., July 1, 2007; 176(1): 49 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. U. Raj, C. Aliferis, R. M. Caprioli, A. W. Cowley Jr., P. F. Davies, M. W. Duncan, D. J. Erle, S. C. Erzurum, P. W. Finn, H. Ischiropoulos, et al. Genomics and proteomics of lung disease: conference summary Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L45 - L51. [Full Text] [PDF] |
||||
![]() |
H. Fehrenbach Animal models of pulmonary emphysema: a stereologist's perspective Eur. Respir. Rev., December 1, 2006; 15(101): 136 - 147. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |